New Data from Biogen’s Investigational Antisense Oligonucleotide (ASO) Targeting Tau Shows Promise for Potential New Generation of Treatments in Early Alzheimer’s Disease Read more
Klaviyo raises IPO range, targeting $9 billion valuation amid tech IPO surge By Investing.com Read more